Image For Activity Cover
Real World Evidence for Clinical Decision Making in Diabetes: Opportunities and Challenges

Real-world data offer great potential to evaluate the effectiveness and safety of diabetes medications in pharmacoepidemiologic studies, when randomized controlled trials are not available, but come with challenges. This webinar will provide an overview of what is real world evidence (RWE) and the considerations when using or interpreting RWE. Many RWE studies can incur substantial bias not from data limitations or lack of randomization, but from avoidable, bias-inducing study design choices.

Dr. Hojin Shin will provide an overview of what is RWE and its potential role in clinical decision-making. Dr. Katsiaryna Bykov will present major sources of avoidable bias in RWE studies of medication safety and effectiveness and discuss potential solutions and current efforts to improve the quality of RWE studies.

Date: Friday, May 17, 2024
Time: 12:00 p.m. - 1:00 p.m. EST

Learning Objectives
  1. To learn what is real world evidence (RWE) in the field of pharmacoepidemiology 
  2. To learn how RWE pertains to diabetes research 
  3. To understand the challenges and considerations when conducting or interpreting RWE research 
Dr. Elisabetta Patorno, Past-Chair, ADA Public Health & Epidemiology Interest Group
Katsiaryna Bykov, PharmD, ScD

Katsiaryna Bykov, PharmD, ScD is an Assistant Professor of Medicine at Harvard Medical School and a pharmacoepidemiologist at the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital. She received her Doctor of Pharmacy degree from Temple University School of Pharmacy in Philadelphia and Doctor of Science in epidemiology at Harvard T.H. Chan School of Public Health in Boston. Dr. Bykov has been working with electronic health care data to evaluate drug utilization, impact of healthcare interventions, and medication safety and effectiveness for more than a decade. Her current research focuses on the development and application of epidemiologic methods for evaluating the safety and effectiveness of complex drug exposures, including extended treatments, combination therapies, and drug-drug interactions. Dr. Bykov is an Associate Editor of Pharmacoepidemiology and Drug Safety and is currently leading the development of a standardized tool for the evaluation of RWE studies on drug safety and effectiveness, funded by the International Society for Pharmacoepidemiology. 

HoJin Shin, BPharm, PhD

HoJin Shin, BPharm, PhD is a postdoctoral research fellow in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital and Harvard Medical School. She holds a Bachelor of Pharmacy and a Master of Pharmacy degrees from Seoul National University (South Korea). She earned her Doctor of Philosophy degree in Population Health Sciences at the Harvard Graduate School of Arts and Sciences and a Master of Science degree in Pharmacoepidemiology at the Harvard T.H. Chan School of Public Health. Her doctoral dissertation focused on evaluating the use of sodium-glucose cotransporter-2 inhibitors, a novel glucose-lowering therapy, as first-line treatment for type 2 diabetes, using large US health insurance claims databases. Her postdoctoral work has been dedicated to bridging the gap between randomized controlled trial (RCT) findings and real-world evidence (RWE). This involves generalizing RCT results to broader populations treated in clinical settings and linking individual trial participants to their claims data to investigate the root causes of discrepancies between RCT results and RWE and assess how each database could complement the other. 


Google Scholar

Availability: No future session
Cost: FREE
Credit Offered:
No Credit Offered
American Diabetes Association 2451 Crystal Drive, Suite 900, Arlington, VA 22202 1-800-DIABETES
Follow us on
Copyright All rights reserved.
Android App Download IOS App Download Powered By